Valaciclovir Bluefish Filmuhúðuð tafla 500 mg 아이슬란드 - 아이슬란드어 - LYFJASTOFNUN (Icelandic Medicines Agency)

valaciclovir bluefish filmuhúðuð tafla 500 mg

bluefish pharmaceuticals ab - valaciclovirum hýdróklóríð - filmuhúðuð tafla - 500 mg

Venlafaxine Bluefish Hart forðahylki 150 mg 아이슬란드 - 아이슬란드어 - LYFJASTOFNUN (Icelandic Medicines Agency)

venlafaxine bluefish hart forðahylki 150 mg

bluefish pharmaceuticals ab - venlafaxinum hýdróklóríð - hart forðahylki - 150 mg

Venlafaxine Bluefish Hart forðahylki 37,5 mg 아이슬란드 - 아이슬란드어 - LYFJASTOFNUN (Icelandic Medicines Agency)

venlafaxine bluefish hart forðahylki 37,5 mg

bluefish pharmaceuticals ab - venlafaxinum hýdróklóríð - hart forðahylki - 37,5 mg

Venlafaxine Bluefish Hart forðahylki 75 mg 아이슬란드 - 아이슬란드어 - LYFJASTOFNUN (Icelandic Medicines Agency)

venlafaxine bluefish hart forðahylki 75 mg

bluefish pharmaceuticals ab - venlafaxinum hýdróklóríð - hart forðahylki - 75 mg

Dabigatran Etexilate Accord 유럽 연합 - 아이슬란드어 - EMA (European Medicines Agency)

dabigatran etexilate accord

accord healthcare s.l.u. - dabigatran etexilate mesilate - venous thromboembolism; arthroplasty, replacement - blóðþurrðandi lyf - prevention of venous thromboembolic events.

Tolvaptan Accord 유럽 연합 - 아이슬란드어 - EMA (European Medicines Agency)

tolvaptan accord

accord healthcare s.l.u. - tolvaptan - Óviðeigandi adh heilkenni - Þvagræsilyf, - tolvaptan is indicated in adults for the treatment of hyponatremia secondary to the syndrome of inappropriate antidiuretic hormone secretion (siadh).

Degarelix Accord 유럽 연합 - 아이슬란드어 - EMA (European Medicines Agency)

degarelix accord

accord healthcare s.l.u. - degarelix acetate - blöðruhálskirtli - other hormone antagonists and related agents - degarelix accord is a gonadotrophin releasing hormone (gnrh) antagonist indicated:for treatment of adult male patients with advanced hormone-dependent prostate cancer. for treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy. as neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer.